Mottola Maria, Bruzzaniti Sara, Piemonte Erica, Lepore Maria Teresa, Petraio Andrea, Romano Renata, Castiglione Antonella, Izzo Lavinia, Perna Francesco, De Falco Chiara, Brighel Federico, Formisano Luigi, Gravina Maria Teresa, Marino Marina, De Feo Marisa, Matarese Giuseppe, Galgani Mario
UOC di Medicina Trasfusionale, AORN dei Colli, Naples, Italy.
Laboratorio di Immunologia, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore," Consiglio Nazionale delle Ricerche, Naples, Italy.
Transplantation. 2025 Apr 1;109(4):638-645. doi: 10.1097/TP.0000000000005201. Epub 2025 Mar 19.
Extracorporeal photopheresis (ECP) has emerged as a prophylactic and therapeutic immunomodulatory option for managing acute rejection in heart transplants (HTx). The underlying mechanisms through which ECP exerts its immunomodulatory effects remain under investigation. Regulatory T cells (Treg) are a heterogeneous subset of immune lymphocytes that ensure the maintenance of tissue homeostasis, avoiding graft rejection. The transcription factor forkhead box protein 3 (FoxP3) is an essential molecular marker of Treg, acting as a "master regulator" of their genesis, stability, and functions. No study has investigated whether ECP impacts FoxP3 expression and its highly suppressive variants containing the exon 2 (FoxP3-E2), particularly in HTx.
In the current study, we recruited 14 HTx participants who had undergone ECP therapy. We explored the effect of in vivo ECP on CD4 + FoxP3 + Treg frequency and in vitro suppressive function in 8 HTx participants before (T0) and after 3 (T1), 6 (T2), and 12 (T3) mo of treatment. As a control group, we included 4 HTx individuals who had not undergone ECP therapy.
We found that ECP increases the frequency of CD4 + FoxP3 + Treg subset with highly suppressive phenotype, including CD4 + FoxP3-E2 + Treg. At functional levels, we observed that ECP treatment in HTx individuals effectively improves Treg suppressive ability in controlling the proliferation of autologous conventional CD4 + T lymphocytes.
Our findings collectively suggest that ECP exerts its immunomodulatory effects in HTx individuals by positively impacting the frequency and regulatory function of the FoxP3 + Treg compartment.
体外光化学疗法(ECP)已成为心脏移植(HTx)中预防和治疗急性排斥反应的一种免疫调节选择。ECP发挥免疫调节作用的潜在机制仍在研究中。调节性T细胞(Treg)是免疫淋巴细胞的一个异质性亚群,可确保组织内环境稳定,避免移植排斥反应。转录因子叉头框蛋白3(FoxP3)是Treg的一种重要分子标志物,是其发生、稳定性和功能的“主调节器”。尚无研究调查ECP是否会影响FoxP3表达及其包含外显子2的高抑制性变体(FoxP3-E2),尤其是在HTx中。
在本研究中,我们招募了14名接受过ECP治疗的HTx参与者。我们在8名HTx参与者治疗前(T0)、治疗3个月(T1)、6个月(T2)和12个月(T3)后,探讨了体内ECP对CD4 + FoxP3 + Treg频率和体外抑制功能的影响。作为对照组,我们纳入了4名未接受ECP治疗的HTx个体。
我们发现ECP增加了具有高抑制表型的CD4 + FoxP3 + Treg亚群的频率,包括CD4 + FoxP3-E2 + Treg。在功能水平上,我们观察到HTx个体接受ECP治疗可有效提高Treg在控制自体常规CD4 + T淋巴细胞增殖方面的抑制能力。
我们的研究结果共同表明,ECP通过积极影响FoxP3 + Treg区室的频率和调节功能,在HTx个体中发挥免疫调节作用。